Emcure Pharmaceuticals Private Limited was incorporated on April 16, 1981, as a private limited company under the Companies Act, 1956. Our name embodies our purpose and core belief of the entire company which is to make effective medicine to cure patients for enabling them to lead healthier lives.
We are a fast-growing Indian pharmaceutical company engaged in developing, manufacturing and marketing a broad range of pharmaceutical products globally. Our core strength lies in developing and manufacturing differentiated pharmaceutical products in-house, which we commercialize through our marketing infrastructure across geographies and relationships with multi-national pharmaceutical companies.
We are ranked as the 12th largest pharmaceutical company (Source: AIOCD Jan MAT 2017) in India in terms of market share based on the domestic sales of pharmaceutical products. We believe that our competitive advantage in the domestic market lies in our established presence in all major therapeutic areas including blood-related, cardiology, pain and analgesics, HIV, gynecology, nephrology, anti-infective, vitamins, minerals, and nutrients products. We have also recently entered the oncology, diabetes and neuroscience therapeutic areas.
We have a well-diversified income base thanks to our business in the international markets. We have our own sales and marketing infrastructure in the United States through our subsidiary, Heritage. We sell our portfolio of branded generic products to the rest of the world. Our products are currently shipped to over 70 countries, where we have established our presence by focusing on important alliances with local and multi-national companies which stand at leadership positions in the therapeutic areas on which we focus. We have subsidiaries in Dubai, Brazil, South Africa, Singapore, Nigeria, branch offices in Russia and Morocco.
We focus our research and development efforts on developing a portfolio of differentiated products across several platforms, including chiral molecules and biosimilars, and novel drug delivery systems. We have a portfolio of 11 chiral molecules, eight of which we launched for the first time in India. We also have capabilities to develop complex products, including difficult iron preparations, oncology drugs, and controlled release products.